Publicaciones
-
Mora J, Climent A, Roldan-Molina M, Flores MC, Varo A, Pérez-Jaume S, Jou-Munoz C, Celma MS, Lazaro JJ, Cheung I, Castañeda-Heredia A, Gorostegui M, Rodriguez E, Chamorro S, Muñoz JP and Cheung NK.
Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects.
Frontiers in oncology . 14: 1380917-1380917.
-
Gorostegui M, Muñoz JP, Pérez-Jaume S, Simao-Rafael M, Cristina Larrosa Espinosa, Garraus-Oneca M, Salvador-Marcos N, Lavarino C, Krauel L, Mañe S, Castañeda-Heredia A and Mora J.
Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy
Cancers . 16(9): . Nº de citas: 1
-
Aschero MR, Ganiewich D, Lamas G, Restrepo-Perdomo CA, Ottaviani D, Zugbi S, Camarero S, Néspoli E, Cuadrado-Vilanova M, Pérez-Jaume S, Pascual-Pastó G, Sampor C, Grigorovski N, Salas B, Suñol M, Carcaboso AM, Mora J, de Dávila MTG, Doz F, Radvanyi F, Abramson DH, Llera AS, Schaiquevich PS, Lubieniecki F and Chantada G.
Immunohistochemical expression of TFF1 is a marker of poor prognosis in retinoblastoma
PEDIATRIC BLOOD & CANCER . 71(1): . Nº de citas: 1
-
Simao-Rafael M, Cruz-Martínez O, Pérez-Jaume S, Santa-María López V, Lavarino C, Salvador-Hernandez H, Muchart-Lopez J, Hinojosa J, Suñol M and Morales-La Madrid A.
Use of bevacizumab in pediatric low-grade glioma: Ten-year experience in a single center
EJC Paediatric Oncology . 2: 100115.
-
Ana Carolina Izurieta Pacheco, Sangrós-Gimenez A, Martínez-Garcia E, Pérez-Jaume S, Mora J and Gorostegui-Obanos M.
Vitamin D Status in Children With High-risk Neuroblastoma
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY . 45(8): 953-958. Nº de citas: 2
-
Muñoz JP, Cristina Larrosa Espinosa, Chamorro S, Pérez-Jaume S, Simao M, Sanchez-Sierra N, Varo A, Gorostegui M, Castañeda-Heredia A, Garraus-Oneca M, Lopez-Miralles S and Mora J.
Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes
Cancers . 15(19): . Nº de citas: 7
-
Gomez-Gonzalez S, Llano-Viles J, Garcia-López M, Garrido- García A, Suñol M, Lemos I, Pérez-Jaume S, Salvador-Marcos N, Gene-Olaciregui N, Galán RA, Santa-María López V, Pérez-Somarriba M, Castañeda-Heredia A, Hinojosa J, Winter U, Moreira FB, Lubieniecki F, Vazquez V, Mora J, Cruz-Martínez O, Morales-La Madrid A, Perera A and Lavarino C.
EpiGe: A machine-learning strategy for rapid classification of medulloblastoma using PCR-based methyl-genotyping
iScience . 26(9): 107598-107598. Nº de citas: 1
-
Esperanza-Cebollada E, Gomez-Gonzalez S, Pérez-Jaume S, Vega-García N, Vicente-Garces C, Richarte M, Rives-Solà S, Català-Temprano A, Torrebadell-Burriel M and Camós-Guijosa M.
A miRNA signature related to stemness identifies high-risk patients in paediatric acute myeloid leukaemia
BRITISH JOURNAL OF HAEMATOLOGY . 202(1): 96-110. Nº de citas: 5
-
Aschero MR, Castillo H, Baulenas-Farrés M, Resa-Parés C, Jiménez-Cabaco A, Rodriguez E, Monterrubio C, Pérez-Jaume S, Suñol M, Chantada G, Lavarino C, Mora J and Carcaboso AM.
Prognostic value of xenograft engraftment in patients with metastatic high-risk neuroblastoma
PEDIATRIC BLOOD & CANCER . 70(6): . Nº de citas: 3
-
Varo A, Castañeda-Heredia A, Chamorro S, Muñoz JP, Gorostegui M, Celma MS, Lopez S, Simao M, Pérez-Jaume S and Mora J.
Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab
Frontiers in oncology . 13: 1164949-1164949. Nº de citas: 4